argenx SE

argenx SE is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Its main approved products include VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). The company also has a robust pipeline with candidates such as efgartigimod for various indications like seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease, myositis, Sjögren's disease, systemic sclerosis, and antibody-mediated rejection (AMR). Other pipeline assets include empasiprubart for multifocal motor neuropathy (MMN), delayed graft function, and CIDP; adimanebart for congenital myasthenic syndrome and spinal muscular atrophy; and early-stage candidates targeting FcRn, IL-6, immunoglobulin A, and Galectin-10. Additionally, argenx has partnerships with Zai Lab for efgartigimod development and commercialization, and with Halozyme Therapeutics for its ENHANZE drug delivery technology.

argenx SE is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ARGX. The company's shares trade in US dollars (USD). As a Netherlands-based company with a US listing, argenx provides investors access to its stock through a major US exchange, facilitating trading in US currency.

argenx operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for autoimmune diseases. The company's work involves advanced biologics, including antibody-based treatments that modulate the immune system to address conditions where the body attacks its own tissues.

argenx SE is headquartered in Amsterdam, the Netherlands. The company operates globally, with a focus on developing and commercializing therapies for autoimmune diseases worldwide. Its approved products, such as VYVGART and VYVGART HYTRULO, are available in multiple countries, and it has strategic partnerships, including with Zai Lab, to expand into markets like China. The company's pipeline targets a broad range of autoimmune conditions, indicating a global market strategy.

argenx generates revenue primarily through the commercialization of its approved therapies, VYVGART and VYVGART HYTRULO, for autoimmune diseases like generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The company also earns from strategic partnerships and license agreements, such as with Zai Lab for efgartigimod development and commercialization in Greater China, and with Halozyme Therapeutics for using its ENHANZE drug delivery technology. Additionally, argenx has collaborations with OncoVerity for cusatuzumab and AbbVie for ARGX-115. Its business model involves advancing a pipeline of novel therapies targeting FcRn, IL-6, and other immune pathways, with potential for future revenue from additional product launches and milestone payments from partners.